Pharmaceutical - UK, Tafinlar

Filter

Current filters:

UKTafinlar

Popular Filters

ESMO 2014: GSK reports 45% survival rate in Tafinlar trial

ESMO 2014: GSK reports 45% survival rate in Tafinlar trial

29-09-2014

UK pharma major GlaxoSmithKline presented data at the European Society for Medical Oncology’s congress…

DacarbazineGlaxoSmithKlineOncologyPharmaceuticalResearchTafinlarUK

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

18-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final draft…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationRocheTafinlarUKZelboraf

NHS England approves GSK’s Tafinlar for funding by UK’s Cancer Drugs Fund

NHS England approves GSK’s Tafinlar for funding by UK’s Cancer Drugs Fund

04-02-2014

GlaxoSmithKline’s Tafinlar (dabrafenib) is now available for metastatic melanoma patients in England…

FinancialGSKOncologyPharmaceuticalRegulationTafinlarUK

GSK’s Tafinlar and Mekinist combo shows improved survival in Phase III study

GSK’s Tafinlar and Mekinist combo shows improved survival in Phase III study

27-01-2014

UK pharma major GlaxoSmithKline announced that its Phase III study of the combination of Tafinlar (dabrafenib)…

GlaxoSmithKlineMekinistOncologyPharmaceuticalResearchTafinlarUK

GSK gains accelerated FDA approval for combination use of Mekinist and Tafinlar

GSK gains accelerated FDA approval for combination use of Mekinist and Tafinlar

09-01-2014

GlaxoSmithKline (LSE: GSK) says that the US Food and Drug Administration has approved Mekinist (trametinib)…

GlaxoSmithKlineMekinistOncologyPharmaceuticalRegulationTafinlarUKUSA

Back to top